Evidence-based cardiovascular care in the community: A population-based cross-sectional study

被引：5

作者：

Putnam W. ^{[1
]}

Burge F.I. ^{[1
]}

Lawson B. ^{[1
]}

Cox J.L. ^{[2
]}

Sketris I. ^{[3
]}

Flowerdew G. ^{[4
]}

Zitner D. ^{[5
]}

机构：

[1] Department of Family Medicine, Dalhousie University, Halifax, NS

[2] Division of Cardiology, Dalhousie University, Halifax, NS

[3] College of Pharmacy, Dalhousie University, Halifax, NS

[4] Dept. of Comm. Hlth. and Epidemiol., Dalhousie University, Halifax, NS

[5] Division of Medical Education, Dalhousie University, Halifax, NS

来源：

BMC Family Practice | / 5卷 / 1期

关键词：

Angiotensin Converting Enzyme; Angiotensin Converting Enzyme Inhibitor; Nova Scotia; Ischaemic Heart Disease; Antithrombotic Agent;

D O I：

10.1186/1471-2296-5-6

中图分类号：

学科分类号：

摘要：

Background: Ischaemic heart disease and congestive heart failure are common and important conditions in family practice. Effective treatments may be underutilized, particularly in women and the elderly. The objective of the study was to determine the rate of prescribing of evidence-based cardiovascular medications and determine if these differed by patient age or sex. Methods: We conducted a two-year cross-sectional study involving all hospitals in the province of Nova Scotia, Canada. Subjects were all patients admitted with ischaemic heart disease with or without congestive heart failure between 15 October 1997 and 14 October 1999. The main measure was the previous outpatient use of recommended medications. Chi-square analyses followed by multivariate logistic regression analyses were used to examine age-sex differences. Results: Usage of recommended medications varied from approximately 60% for beta-blockers and angiotensin converting enzyme (ACE) inhibitors to 90% for antihypertensive agents. Patients aged 75 and over were significantly less likely than younger patients to be taking any of the medication classes. Following adjustment for age, there were no significant differences in medication use by sex except among women aged 75 and older who were more likely to be taking beta-blockers than men in the same age group.

引用

页码：1 / 23

页数：22

共 37 条

[1]

1997 Consensus conference on the evaluation and management of chronic ischemic heart disease, Can J Cardiol, 14, (1998)

[2]

Rochon P.A., Anderson G.M., Tu J.V., Clark J.P., Gurwitz J.H., Szalai J.P., Lau P., Use of β-blocker therapy in older patients after acute myocardial infarction in Ontario, Can Med Assoc J, 161, pp. 1403-1408, (1999)

[3]

Rochon P.A., Anderson G.M., Tu J.V., Gurwitz J.H., Clark J.P., Shear N.H., Lau P., Age- and gender-related use of low-dose drug therapy: The need to manufacture low-dose therapy and evaluate the minimum effective dose, J Am Geriatr Soc, 47, pp. 954-959, (1999)

[4]

Rojas-Fernandez C.H., Kephart G.C., Sketris I.S., Kass K., Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: Data from the 1995 population-based Nova Scotia Health Survey, Can J Cardiol, 15, pp. 291-296, (1999)

[5]

Khan N., Chockalingam A., Campbell N.R.C., Lack of control of high blood pressure and treatment recommendations in Canada, Can J Cardiol, 18, pp. 657-661, (2002)

[6]

Cox J.L., Optimizing disease management at a health care system level: The improving Cardiovascular Outcomes in Nova Scotia (ICONS) Study, Can J Cardiol, 15, pp. 787-796, (1999)

[7]

ATC Index with DDDs, (2001)

[8]

Cohn J.N., Tognoni G., A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, pp. 1667-1675, (2001)

[9]

Anand S.S., Yusuf S., Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis, JAMA, 282, pp. 2058-2067, (1999)

[10]

SAS/STAT Version 8.2, (1999)

← 1 2 3 4 →